Highlights Quarter three revenue was $2,042.8 million representing an increase of 1.3% on quarter two 2025. Net income for the quarter was $2.4 million or $0.03 per diluted share. Quarter ...

Prior authorization can help encourage the efficient use of health care resources but too often, it delays treatment patients ...

The medtech industry desperately needs — and currently lacks — a practical trial-specific financial framework to build a ...

The CARL® ECPR system’s nomination for the Prix Galien USA 2025 Award in the “Best Startup” Category underscores its ...

ICON plc (NASDAQ: ICLR), a world-leading clinical research organization, today reported its financial results for the third quarter ended September 30, 2025.

About one-third of all drugs approved by the Food and Drug Administration target the largest family of cell membrane ...

This detailed look at the collaboration driving new capabilities in ultrafast laser processing systems includes a Q&A with ...

Real-world evidence (RWE) data estimate 19.8% relative vaccine effectiveness (rVE) of cell-based quadrivalent influenza vaccines (QIVc) versus standard ...

Pharmaceutical Market, Artificial Intelligence, Personalized Medicine, Digital Transformation, Supply Chains, Regulatory ...